Remaining Claims in Pamidronate MDL Preempted, Judge Rules

NEW YORK - A New York federal judge has dismissed the remaining claims in the generic Aredia (pamidronate) multidistrict litigation, ruling that they are preempted by the U.S. Supreme Court's recent ruling in Pliva Inc. v. Mensing. Bartoli, et al. v. APP Pharmaceuticals Inc., et al., Nos. 09-MD-2120 and 10-CV-1860 (E.D. N.Y.).

On Jan. 30, Judge Kiyo Matsumoto of the U.S. District Court for the Eastern District of New York found that plaintiffs sought to impose state law requirements that would have been impossible for the drug makers to implement in accordance with federal law.

Plaintiffs sued APP Pharmaceuticals Inc., …